



ISSN Print: 2394-7500
ISSN Online: 2394-5869
Impact Factor: 8.4
IJAR 2023; 9(8): 40-43
www.allresearchjournal.com
Received: 05-06-2023
Accepted: 04-07-2023

Dr. Anitha S Maiya
Professor, M.S., FAEHG,
Department of
Ophthalmology, JJMMC,
Davangere, Karnataka, India

Dr. Anusha J
MBBS, Resident, Department
of Ophthalmology, JJMMC,
Davangere, Karnataka, India

Correlation of diabetic peripheral neuropathy with peripapillary retinal nerve fibre layer thickness in patients with type 2 diabetes mellitus

Dr. Anitha S Maiya and Dr. Anusha J

Abstract

Context: To correlate Diabetic peripheral neuropathy with peripapillary retinal nerve fibre layer thickness in patients with type 2 diabetes mellitus.

Aims: To correlate peripapillary retinal nerve fibre layer thickness of DM patients with Diabetic peripheral neuropathy.

Settings and Design: Cross-sectional analytical study.

Methods and Material: This hospital based cross-sectional study included patients attending the outpatient department of our institution with the following criteria, 50 subjects diagnosed with type 2 diabetes mellitus were included.

Results: It showed a significant (0.014) thinning of global peripapillary retinal nerve fibre layer thickness in left eyes with diabetic peripheral neuropathy positive comparison to no diabetic peripheral neuropathy patients. There was no significant difference in the right eye.

Conclusions: Individuals with diabetic peripheral neuropathy showed significant thinning in peripapillary retinal nerve fibre thickness. This may suggest a common pathway of neurodegeneration for both these complication. Peripapillary retinal nerve fibre layer thickness can be used as a means of screening for diabetic peripheral neuropathy to improve the efficiency of clinical diabetic peripheral neuropathy detection.

Keywords: A significant association present between DR, DPN and their severities. The neurodegenerative changes are in parallel to DPN in the course of DM. Peripapillary RNFL thickness can be used as a means of screening for DPN to improve the efficiency of clinical DPN detection

Introduction

Type 2 Diabetes mellitus (DM) is a multifactorial metabolic disease characterized by sustained hyperglycaemia leading to long term complications such as Diabetic retinopathy (DR), nephropathy and diabetic peripheral neuropathy (DPN) and other vascular complications.

Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycaemia [1]. The prevalence of type 2 DM in world was 9.3% [2] and in India was between 10.9 and 14.2% in 2019 [3].

DPN is the most common component in the causal sequelae to foot ulceration. The prevalence of DPN in DM estimates to 50% as studied in the previous literature [4]. Pfeiffer *et al.*, studied that among 7.5% of the participants, 45% developed DPN after 25 years of follow up [5]. Abbott *et al* studied that a large cohort of people with DPN developed diabetic foot after one year.

Since the gold standard diagnostic tool in the diagnosis is Nerve conduction studies (NCS) and Electro-diagnostic tests such as Electro Myography (EMG) [6], since they cannot be used for the routine diagnosis due to availability issues, we used an alternate method and diagnosed with the index test Michigan neuropathy screening instrument (MNSI) [7].

Retinal neurodegenerative changes in DR have been shown to precede micro vascular changes in some previous studies, also known as Diabetic retinal neurodegeneration (DRN) caused by neuronal apoptosis and glial cell activation resulting in thinning of PRNFLT even in the absence of DR progression.

DPN ranks third after the micro vascular disease and nephropathy in lifetime expenditures and is a large burden in a developing country like India.

Corresponding Author:
Dr. Anusha J
MBBS, Resident, Department
of Ophthalmology, JJMMC,
Davangere, Karnataka, India

The cost of long term treatment and dependency becomes much heavier, when the patient with DPN progress to diabetic foot and it's complications.

In a study by Rehna Rasheed *et al.* [8], studied that there was a significant association of DPN and DR, and early changes in inner retinal layers of diabetic patients without microvascular changes of DR and these neurodegenerative changes parallel with DPN in the course of DM.

Thus, the early screening and diagnosis of DPN helps in the early intervention in the form of enhanced glucose control and neuro-protective agents, thus preventing the patient landing in devastating complications of diabetic foot leading to foot amputation. Hence, this study was conducted to correlate DPN with peripapillary RNFL thickness in type 2 diabetics.

Subjects and Methods

This cross-sectional study was carried out between February 2021 and August 2022, after approval from institutional ethical committee and taking written informed consent from patients. Patients of either gender aged 41-60 years, either normal individuals or with the diagnosis of type 2 DM were included.

Patients with glaucoma, proliferative DR (PDR), congenital optic disc anomalies, optic neuropathies, ocular trauma, previous retinal laser photocoagulation, media opacities, high refractive errors $\geq \pm 6D$, and poor OCT strength < 6 were excluded. Demographic data of study population was acquired. Patients fulfilling the above criteria were included. All patients underwent a comprehensive ophthalmic examination with measurement of best corrected visual acuity (BCVA), anterior and posterior segment examination with staging of DR (According to ETDRS classification) [9]. Peripapillary RNFL thickness measurements were taken using Cirrus HD OCT (Carl Zeiss Meditec) after pupillary dilatation with 0.8% Tropicamide + 5% phenylephrine eye drops. Global as well as mean peripapillary RNFL thickness of all four quadrants was taken.

SPSS (version 17, IBM) was used for statistical analysis. Descriptive statistics (mean \pm SD) for quantitative values (age, RNFL) and frequencies with % for qualitative variables were used to describe the data. Quantitative variables were compared between the groups using one way ANOVA test. A p value of ≤ 0.05 was considered statistically significant.

Screening for DPN – Index test Michigan Neuropathy Screening Instrument (MNSI) [10]

- Q (15)- Sensory symptoms, cramps, muscle weakness, foot ulcer;
- E-Foot appearance, ankle reflex 128 HZ tuning fork.

DPN + DPN-

Q > 7; E > 2 Q < 7; E < 2

Results

1. Patient characteristics

In our study, out of 50 diabetic's patients, there were 26 males and 24 females. Mean age was 54.38 ± 6.12 years.

There were 15 patients (66% of the patients were in age group 56-60 years) who had DPN, and 35 patients who had no DPN. There was no difference in gender distribution.

DPN positive patients had duration of DM > 10 years and HbA1c > 7%.

The age of the patients in this study ranged from 41 to 60 years and the age-wise distribution of patients is as shown in table 1.

We compared the BCVA in log MAR among the normal subjects with the DM groups and found a significant reduction of BCVA in DPN positive patients compared to no DPN patients in both the eyes.

2. Correlation of global peripapillary RNFL thickness with DPN

As depicted in table 2, there was a significant thinning of peripapillary RNFL thickness in patients where DPN was present in the left eyes in comparison to no DPN patients, similar to the study by Rehna Rasheed *et al.* [2] and Cirous Dehghani *et al.* [3].

Discussion

Age and gender

Our study population age group ranged from 41 to 60 years. The study included 26 males and 24 females. As per the Barbados Eye Study [11] most of the diabetic patients were in the age group of 50-64 years, which is similar to our study. Also in a study by Rania, *et al.* [12] majority of the DM patients were in the age group of 40-59 years. The prevalence of vision threatening DR were most among the age group of 50-64 years as well.

Among the 50 diabetic patients, 26 (52%) were females and 24 (48%) were males.

As per the previous studies such as Barbados Eye Study, Barbados conducted from 1988-1992 show that females were prone for diabetes. Also in a study by Irimi Chatzivalli [13] *et al.* females were more, but in contradiction males were more in the study conducted by Rania *et al.*

However, in our study we had almost equal number of males and females.

BCVA in DM

There was a significant reduction of BCVA in DPN positive patients compared to no DPN patients in both the eyes. Our study results were similar to the study by Jin li *et al.* [14] and is correlated to micro vascular ischaemia and retinal neurodegeneration in DR, greater levels of DR severity corresponded to worse vision.

Correlation of global peripapillary RNFL thickness with DPN

In our study, we found significant thinning of peripapillary RNFL thickness in both the eyes of DPN positive patients in comparison to no DPN patients. Peripapillary RNFL thinning in diabetics is explained by diabetic retinal neurodegeneration. DRN can be attributed to various factors resulting in neuronal degeneration from metabolic derangements, reactive gliosis, glutamate excitotoxicity and nerve fibre layer and ganglion cell apoptosis, which results in thinning of peripapillary RNFL thickness.

DPN mostly affects the lower limbs and the feet, and in some cases upper limb also affected. It is a chronic, symmetrical condition affecting multiple nerves. DPN of the limbs increases with increasing age and DM duration. It is associated with suboptimal glycaemic control and obesity following a stocking glove pattern. It often starts at the distal end of the long nerves and moves proximally. All the patients with DM (both types 1 and 2) should undergo DPN screening.

Our study results were similar to the study by Rehna Rasheed *et al.*, [16] studied that there was a significant association of DPN and DR, and early changes in inner retinal layers of diabetic patients without microvascular changes of DR and these neurodegenerative changes parallel with DPN in the course of DM.

As recommended by the 1988 consensus statement from the San Antonio conference on Diabetic neuropathy, for the diagnosis and classification of DPN multiple tests, quantitative sensory testing and autonomic function testing is required.

Table 1: Demographic data

| Characteristics | DPN + | DPN- |
|---------------------------|-------|------|
| 1. Age | | |
| 41-45 | - | 12 |
| 46-50 | 2 | 10 |
| 51-55 | 3 | 10 |
| 56-60 | 10 | 3 |
| 2. Gender | | |
| Male | 8 | 18 |
| Female | 7 | 17 |
| 3. BCVA | | |
| < 6/60 | - | - |
| 6/60-6/18 | 3 | - |
| > 6/12 | 12 | 35 |
| 4. Duration of DM (years) | 10.36 | 6.1 |
| 5. HbA1c | | |
| < 7% | 13 | 25 |
| > 7% | 2 | 10 |

Table 2: Comparison of global PRNFLT with DPN

| Global PRNFLT | DPN + | DPN - | t | P |
|---------------|-------|-------|------|--------|
| RE mean | 85.76 | 84 | 1.31 | 0.2 |
| LE mean | 82.79 | 88.22 | 2.55 | 0.014* |

Conclusion

Individuals with DPN showed significant reduction in peripapillary RNFL thickness. This may suggest a common pathway of neurodegeneration for both these complication.

- There is a significant association between DR, DPN and their severities. The neurodegenerative changes are in parallel to DPN in the course of DM.
- Peripapillary RNFL thickness can be used as a means of screening for DPN to improve the efficiency of clinical DPN detection.

DPN screening in the early diagnosed DR patients helps to know patients at the earliest and thus, helpful in early therapeutic approach in the prevention of diabetic foot complications.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- Powers AC, Niswender KD, Molina CE. Endocrinology and Metabolism. In: J. Larry Jameson. Harrison's Principles of Internal Medicine, 20th Ed. New Delhi: McGraw – Hill Education; c2018. p. 2850.
- Pouya Saeedi, Inga Petersohn, Paraskevi Salpae, Dominic Bright, Rhys Williams, *et al.* Global and

regional Diabetes prevalence estimates for 2019 and projections for 2030 and 2045. Results from the International diabetes federation Diabetes atlas. Diabetes Research and Clinical Practice.

DOI: <https://doi.org/10.1016/j.diabres.2019.107843>

- Sharma NC. Government survey found 11.8% prevalence of diabetes in India. 10th October 2019. Published On: <https://www.livemint.com/science/health/government-survey-found-11-8-prevalence-of-diabetes-in-india-11570702665713.html>
- Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy: A continuing enigma. Diabetes Metab Res Rev. 2000 Nov-Dec;16(6):408-33.
- Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes. 1995 Dec;44(12):1355-61.
- England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, *et al.* American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve. 2009 Jan;39(1):106-15.
- Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, *et al.* A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994 Nov;17(11):1281-9.
- Rasheed R, Pillai GS, Kumar H, Shajan AT, Radhakrishnan N, Ravindran GC. Relationship between diabetic retinopathy and diabetic peripheral neuropathy - Neurodegenerative and microvascular changes. Indian J Ophthalmol. 2021 Nov;69(11):3370-3375.
- Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, *et al.* Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. American journal of ophthalmology. 2008 May 1;145(5):894-901.
- Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, *et al.* A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994 Nov;17(11):1281-9
- yan SJ. The epidemiology of Diabetic Retinopathy. In: Ryan SJ (Ed). Retina, 5th edition. Philadelphia, PA: Elsevier Saunders; c2013. p. 1019.
- Fahmy RM, Bhat RS, Al-Mutairi M, Aljaser FS, El-Ansary A. Correlation between glycemic control and peripapillary retinal nerve fiber layer thickness in Saudi type II diabetics. Clinical Ophthalmology (Auckland, NZ). 2018;12:419.
- Chatziralli I, Karamaounas A, Dimitriou E, Kazantzis D, Theodossiadis G, Kozobolis V, *et al.* Peripapillary Retinal Nerve Fiber Layer Changes in Patients with Diabetes Mellitus: A Case-control Study. Semin Ophthalmol. 2020 May 18;35(4):257-260.
- Li J, Zhou Y, Chen F, *et al.* Visual acuity is correlated with ischemia and neurodegeneration in patients with early stages of diabetic retinopathy. Eye and Vis. 2021;8:38.
- Dwijayanti S, Kartasmita A, Sovani I, Iskandar E, Virgana R, Ihsan G. Peripapillary Retinal Nerve Fiber

- Layer Thickness in Diabetic Retinopathy Patients measured by Optical Coherence Tomography. *International Journal of Retina*. 2018 Aug 24;1:2.
16. Rasheed Rehna, Pillai Gopal S, Kumar Harish1, Shajan Adish Thayyil, Radhakrishnan Natasha, *et al.* Relationship between diabetic retinopathy and diabetic peripheral neuropathy - Neurodegenerative and micro vascular changes, *Indian Journal of Ophthalmology*: November. 2021;69(11):3370-3375.